In another retrospective study (35), among 45 unresectable stage III NSCLC patients receiving radiotherapy with EGFR-TKI, 17 patients (37.7%) suffered radiation pneumonitis, but achieved satisfactory PFS and OS: 27.9 (95% CI: 18.7–37.2) and 49.7 (95% CI: 27.7–71.8) months. This evidence concerns the gene EGFR and non-small cell lung carcinoma.